Aptose Biosciences Inc (APTO)

[Tartiaboy]

APTO hopes to develop TUSP for front line AML (in triplet combination). They think it may be approvable for front line FLT3 positive AND negative patients. They also believe that if it is as effective as they hope it could be used in BOTH fit and unfit AML patients. i.e. virtually every AML patient could be treated frontline with the triple combination of HMA:VEN:TUSP. In addition, TUSP is going to be tested with VEN for MDS patient. APTO believes this makes TUSP a BIG PHARMA class molecule. i.e. easily $1B+ market. That may take seven + years. BUT! I do not think APTO will ever take it to that level without major BIG PHARMA involvement.

Right now the focus is on proving that TUSP is this type of drug and courting BIG PHARMA interest. I think BP will become a major factor within TWO to THREE years.